BSX was down some 1% Wednesday afternoon at $26.04 after sliding 7% Tuesday on word of delays in commercialization of the firm's Lotus Edge Aortic Valve System.
Boston Scientific now hopes to reintroduce the device in Europe next quarter and file a final Pre-Market Approval (PMA) module with the U.S. Food and Drug Administration by January 2018.
But despite this delay and the stock's subsequent drop, JPMorgan analysts see the weakness as a buying opportunity. Late Tuesday night, they reiterated their "Overweight" rating and $31 price target on Boston Scientific's stock. JPM's analysts argued that regardless of the Lotus' delay, BSX will still be able to grow revenue and generate double-digital earnings-per-share growth.
"Investor confidence in Lotus will take some time to improve," the analysts wrote in a note. "But even if one takes Lotus out of the model, one can still make a case for 6%-7% revenue growth and double-digit EPS growth through the end of the decade, which still puts BSX at the high end of its peers."
(This article has been updated to include a late-afternoon stock price.)
More of What's Trending on TheStreet: